Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy

System of Care to Advance Care for the Most Commonly Inherited Heart Disease

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) --  Cytokinetics, Inc. (Nasdaq: CYTK) today announced its support of a three-year initiative led by the American Heart Association to address disparities in access to care, diagnosis, and treatment for people living with hypertrophic cardiomyopathy (HCM), a chronic and often underdiagnosed heart disease that affects hundreds of thousands of individuals across the United States. As a supporter of this multi-stakeholder undertaking, Cytokinetics will contribute its longstanding commitment to the HCM community to help close prevailing gaps between evidence, guidelines, implementation, and equity in healthcare delivery for HCM.

“Too many patients living with HCM face a lack of awareness about their condition, delayed diagnoses, and limited access to specialty care,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “We are proud to support the American Heart Association to advance a more standardized and comprehensive system of care. This important initiative aligns with our science and patient-centric company culture and reinforces our commitment to elevate the standard of care for those living with HCM.”

An estimated one in 500 people in the U.S. are living with HCM but many remain undiagnosed or untreated until acute symptoms occur. This underdiagnosis has led to inconsistent and fragmented systems of care. The American Heart Association initiative seeks to identify systemic barriers to improve HCM systems of care and improve how patients with HCM are identified, assessed, referred, and treated.

Cytokinetics’ support will build on a national effort to unify and elevate care for HCM patients by:

• increasing the number of sites participating in a national HCM Registry powered by Get With The Guidelines;
• broadening certification opportunities for referring centers and personnel to reach more communities and patients;
• introducing patient support services at key HCM diagnosis and treatment centers; and 
• implementing a prospective pilot of the Association’s HCM detection algorithm designed to reduce underdiagnosis. 

“Cytokinetics’ participation underscores the importance of working across sectors to advance heart health,” said Anjali Owens, M.D., co-chair of the American Heart Association’s HCM initiative. “HCM is often inconsistently managed, leading to delayed treatment, increased risk of complications and preventable death. With this added support, we will work to drive meaningful change that empowers patients, informs clinicians, and strengthens the care continuum for HCM.”